Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 15/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019027 | 0.92 | ECE1 (0.50) | ECE1MMEACE | |
| SCHEMBL6776727 | 0.87 | ECE1 (0.48) | ECE1MMEACEPPARA | |
| SCHEMBL6781829 | 0.84 | ECE1 (0.44) | ECE1MMEACEPPARA | |
| SCHEMBL6773549 | 0.82 | NLRP3 (0.46) | ECE1MMEACE | |
| SCHEMBL6774432 | 0.81 | SIRT2 (0.51) | ECE1SIRT2 | |
| SCHEMBL6776402 | 0.81 | ECE1 (0.49) | ECE1MMEACE | |
| SCHEMBL6770606 | 0.81 | ECE1 (0.49) | ECE1MMEACE | |
| SCHEMBL6774628 | 0.80 | ECE1 (0.64) | ECE1MMEACE | |
| SCHEMBL6774623 | 0.80 | ECE1 (0.64) | ECE1MMEACE | |
| SCHEMBL7012794 | 0.80 | ECE1 (0.55) | ECE1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1186344-C | Amino acid compounds and their use as NEP, ACE and ECE inhibitors | INST NAT RECH MEDICALE INSERM (FR) | 2005-01-26 | — | — | CN | disclosed |
| US-6716852-B2 | FOR THERAPY OF ARTERIAL HYPERTENSION AND CARDIOVASCULAR DISEASES | LES LABORATORIES SERVIER (FR) | 2004-04-06 | — | — | US | disclosed |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | LES LABORATOIRES SERVIER (FR) | 2003-03-20 | — | — | US | disclosed |
| CN-1400974-A | Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors | INST NAT RECH MEDICALE INSERM (FR) | 2003-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | MME, ACE, ECE1 | ECE1 3/4885MME 1/4885ACE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.